Please Wait
Applying Filters...
menu
    • menu
    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

    Virtual Booth

    Contact Supplier

    Boai NKY Pharmaceuticals Ltd. is one of the largest global PVP suppliers.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-06-09

    Virtual Booth

    An Enquiry

    Menu

    Taletrectinib

    DEVELOPMENTS

    DIGITAL CONTENT

    MARKET PLACE

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    US FDA approves Nuvation Bio's rare lung cancer drug
    US FDA approves Nuvation Bio's rare lung cancer drug

    12 Jun 2025

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-nuvation-bios-lung-cancer-therapy-2025-06-11/

    REUTERS
    12 Jun 2025
    Share Share
    Nuvation Bio to Present New Data on Taletrectinib at ASCO 2025
    Nuvation Bio to Present New Data on Taletrectinib at ASCO 2025

    21 May 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250521881222/en/Nuvation-Bio-To-Present-New-Data-from-Pivotal-Clinical-Studies-of-Taletrectinib-in-Advanced-ROS1-Positive-Non-Small-Cell-Lung-Cancer-at-ASCO-2025-Annual-Meeting

    BUSINESSWIRE
    21 May 2025
    Share Share
    Nuvation Bio to Present Data for Taletrectinib vs. Entrectinib
    Nuvation Bio to Present Data for Taletrectinib vs. Entrectinib

    13 May 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250513735131/en/Nuvation-Bio-to-Present-Matching-adjusted-Indirect-Comparison-Data-for-Taletrectinib-vs.-Entrectinib-at-ISPOR-2025

    BUSINESSWIRE
    13 May 2025
    Share Share
    Nuvation Bio to Present Nonclinical Data at AACR Meeting 2025
    Nuvation Bio to Present Nonclinical Data at AACR Meeting 2025

    25 Mar 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250325813594/en/Nuvation-Bio-to-Present-New-Nonclinical-Data-for-Taletrectinib-at-the-American-Association-for-Cancer-Research-Annual-Meeting-2025

    BUSINESSWIRE
    25 Mar 2025
    Share Share
    Nuvation To Present Taletrectinib Vs. Crizotinib Data At Lung Congress
    Nuvation To Present Taletrectinib Vs. Crizotinib Data At Lung Congress

    25 Mar 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250325247942/en/Nuvation-Bio-to-Present-Matching-adjusted-Indirect-Comparison-Data-for-Taletrectinib-vs.-Crizotinib-During-Mini-Oral-Presentation-at-the-European-Lung-Cancer-Congress-2025

    BUSINESSWIRE
    25 Mar 2025
    Share Share
    Nuvation Bio Launches US Expanded Access Program for Taletrectinib
    Nuvation Bio Launches US Expanded Access Program for Taletrectinib

    03 Feb 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250203001473/en

    BUSINESSWIRE
    03 Feb 2025
    Share Share